{"id":954166,"date":"2026-04-23T08:24:03","date_gmt":"2026-04-23T12:24:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/"},"modified":"2026-04-23T08:24:03","modified_gmt":"2026-04-23T12:24:03","slug":"shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/","title":{"rendered":"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MILWAUKEE, April  23, 2026  (GLOBE NEWSWIRE) &#8212; Ademi LLP is investigating Soleno (NASDAQ: SLNO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Neurocrine.<\/p>\n<p>Click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EIcibrJ19PI0jwrEAHbDiR9tCTzzln3iJ1PLKhT_Y2gzhyKok1ooLFFajU3d0tZKyhLLaRTfLd4mr__mTa3MxSkCuVCB94ljB9mYx884yXoUqAvA4-KWYogz-3Cg48x1\" rel=\"nofollow\" target=\"_blank\">here<\/a> to learn how to join our investigation and obtain additional information or contact us at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DUwZXSDF3m-hHfyam1BEhV9SdILqWf2h43fsDMprHHtHk5FqfaiyIHcvfAVUMxH98o_uHc2s3jlwkoADb4cqHiDgVlTKog1sy-vZ83Q5H7I=\" rel=\"nofollow\" target=\"_blank\">gademi@ademilaw.com<\/a> or toll-free: 866-264-3995. There is no cost or obligation to you.<\/p>\n<p>In the transaction, Soleno and its shareholders will receive $53.00 per share, representing a total transaction equity value of $2.9 billion.<\/p>\n<p>The transaction agreement unreasonably limits competing transactions by imposing significant penalties if the parties accept competing bids. We are investigating the conduct of the Soleno board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.<\/p>\n<p>We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>Contacts<\/p>\n<p>Ademi LLP<br \/>Guri Ademi<br \/>Toll Free: (866) 264-3995<br \/>Fax: (414) 482-8001<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTgzNmMwOTUtNmVkYi00YzBmLTliYTYtZDY5MTgxOTQ4NzdmLTEwMjkyMTUtMjAyNi0wNC0yMy1lbg==\/tiny\/Ademi-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MILWAUKEE, April 23, 2026 (GLOBE NEWSWIRE) &#8212; Ademi LLP is investigating Soleno (NASDAQ: SLNO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Neurocrine. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Soleno and its shareholders will receive $53.00 per share, representing a total transaction equity value of $2.9 billion. The transaction agreement unreasonably limits competing transactions by imposing significant penalties if the parties accept competing bids. We are investigating the conduct of the Soleno board of directors, and whether they are fulfilling their fiduciary duties to all &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954166","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MILWAUKEE, April 23, 2026 (GLOBE NEWSWIRE) &#8212; Ademi LLP is investigating Soleno (NASDAQ: SLNO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Neurocrine. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Soleno and its shareholders will receive $53.00 per share, representing a total transaction equity value of $2.9 billion. The transaction agreement unreasonably limits competing transactions by imposing significant penalties if the parties accept competing bids. We are investigating the conduct of the Soleno board of directors, and whether they are fulfilling their fiduciary duties to all &hellip; Continue reading &quot;Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T12:24:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders\",\"datePublished\":\"2026-04-23T12:24:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/\"},\"wordCount\":177,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/\",\"name\":\"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=\",\"datePublished\":\"2026-04-23T12:24:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/","og_locale":"en_US","og_type":"article","og_title":"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders - Market Newsdesk","og_description":"MILWAUKEE, April 23, 2026 (GLOBE NEWSWIRE) &#8212; Ademi LLP is investigating Soleno (NASDAQ: SLNO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Neurocrine. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Soleno and its shareholders will receive $53.00 per share, representing a total transaction equity value of $2.9 billion. The transaction agreement unreasonably limits competing transactions by imposing significant penalties if the parties accept competing bids. We are investigating the conduct of the Soleno board of directors, and whether they are fulfilling their fiduciary duties to all &hellip; Continue reading \"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-23T12:24:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders","datePublished":"2026-04-23T12:24:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/"},"wordCount":177,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/","name":"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=","datePublished":"2026-04-23T12:24:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NTgwOCM3NTUyNDIxIzIwMTc2NDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-soleno-therapeutics-inc-s-transaction-with-neurocrine-is-fair-to-public-shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.\u2019s Transaction with Neurocrine is Fair to Public Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954166"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954166\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}